About Illumina
Illumina is a publicly listed company based in San Diego (United States) founded in 1993 by Mark Chee and Larry Bock. It operates in the Healthcare and Technology sectors. Illumina has raised $28 million across 11 funding rounds from investors including State Farm, United States Department of Agriculture and HHS. The company has 29 employees. Illumina has completed 16 acquisitions, including Advanced Liquid Logic, Affomix and Bluebee. Its website illumina.com draws about 673 thousand monthly visits. Its Indian entity Illumina India Biotechnology Private Limited reported revenue of ₹290 Cr. Its focus areas include High Tech, Nanotechnology, Nanotools and Genomics. Its competitors include DNAnexus, Seven Bridges Genomics and Hexagon Bio; 3 of its 3 listed competitors have raised funding.
Company details
Developer of technologies for analysis of genetic variation and function. The company provides laboratory instruments, kits, and reagents for research, drug development, and the development of molecular tests. The product categories include gene panel and array finder, microarray kits, clinical research, and IVD products.
- Headquarters San Diego, United States
- Employees 29
- Founders Mark Chee, Larry Bock
- Stage Public
- SectorsHealthcareTechnology
- Website category Science and Education · Biology
- Email••••••••
- Phone•••• ••••
- Website illumina.com
- Social LinkedIn X
- Legal Name Illumina India Biotechnology Private Limited
- Date of Incorporation 20 Jun, 2018
- Jurisdiction Haryana, India
- Indian entity revenue₹290 Cr
FY 2025 · +41% YoY
- Indian entity net profit₹12.67 Cr
FY 2025 · 4% margin
- Indian entity EBITDA₹46.88 Cr
FY 2025 · 16% margin
- Total Equity Funding$28M (USD)
in 11 rounds
- InvestorsState Farm
& 13 more
- Employee Count29
- Investments & AcquisitionsAdvanced Liquid Logic
& 15 more
Associated legal entities of Illumina
Illumina operates through Illumina India Biotechnology Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Illumina India Biotechnology Private Limited CIN U51100HR2018FTC074675 | Active | 20 Jun 2018 | ₹290 Cr | 29 | 3 | View details |
Funding Insights of Illumina
Illumina has successfully raised a total of $28M across 11 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $28M
- Total Rounds 11
- First Round $28M
(Jan 2000)
- Investors Count 14
Latest 10 of 11 funding rounds of Illumina with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2020 | Grant | – | – | ||
| Aug 2019 | $55,392 | Grant | – | – | |
| Aug 2014 | $346,925 | Grant | – | – | |
| Sep 2010 | $5.62M | Grant | – | – | |
| Jun 2009 | $243,011 | Grant | – | – | |
| Aug 2008 | $300,000 | Grant | – | – | |
| May 2008 | $203,745 | Grant | – | – | |
| Sep 2007 | $5.62M | Grant | – | – | |
| Sep 2004 | $5.62M | Grant | – | – | |
| Aug 2004 | $1.2M | Grant | – | – |
14 investors in total: 14 institutional.
Investors in Illumina
Illumina has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include State Farm, United States Department of Agriculture and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Seed & early stage multiple stage focused corp VC firm funding companies in the US and Canada | chevron.com/technology/technology-ventures | Houston, United States | ||
Early-stage healthcare startups are invested in by CW Ventures. | cwventures.com | New York, United States | ||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
| niaid.nih.gov | ||||
Provider of wealth management services | 1796 | lombardodier.com | Geneva, Switzerland | |
Insurance and financial services are provided to individuals and businesses. | 1922 | statefarm.com | Bloomington, United States | |
Business strategy consulting services are provided to corporate clients. | 1949 | pecs.co.za | Cape Town, South Africa |
Investor details for Illumina
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Illumina India Biotechnology Private Limited (Illumina)
Illumina India Biotechnology Private Limited is the primary company behind Illumina. The board of Illumina India Biotechnology Private Limited currently have 3 directors; the longest-serving is Frederic Didier Mahieu, appointed in 2023. 7 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Frederic Didier Mahieu DIN 10388796 | Director | 20 Nov 2023 | 2 yrs 11 mo | Illumina India Biotechnology Private Limited |
| Ramesh Thamotharan DIN 09548894 | Whole-time director | 03 Sep 2025 | 1 yr 1 mo | Illumina India Biotechnology Private Limited |
| Amitabh Rath DIN 11284260 | Whole-time director | 08 Sep 2025 | 1 yr 1 mo | Illumina India Biotechnology Private Limited |
People of Illumina
739 people are tracked at Illumina (193 in leadership, 10 in board & advisors, 536 in team); the tracked headcount is 29.
| Name | Role | Group |
|---|---|---|
Mark Chee | Co-Founder | Leadership |
Larry Bock | Co-Founder | Leadership |
Joe Cascio | Senior Director - Global Sales Performance Management | Leadership |
Michael Moe | Staff Talent Acquisition Partner | Leadership |
Joann MacIejewski | Director, Executive Search And Corporate Functions Talent Acquisition | Leadership |
Ashish Shah | Sr Director, Data & Analytics | Leadership |
Jennifer Richardson | Director, AMR Marketing Events | Leadership |
Katie Molek | Director Talent Acquisition | Leadership |
Lisandra Mioni-Green | Associate Director, Global Mobility & Immigration | Leadership |
Adeline Low | Vice President Global Operations Shared Services | Leadership |
Jo Lee | Associate Director, Talent Acquisition - Europe | Leadership |
Norbert Keller | Sr. Director EMEA Supply Chain And Eindhoven Site Head | Leadership |
Amar Nayak | Associate Director - Data Architecture And Engineering | Leadership |
Viviane Windmiller | Global Head Of Employment, General Practice & Real Estate Law | Leadership |
Wilfred Li | Director, Software And Bioinformatics | Leadership |
David Mok | Vice President, Pricing, Analytics & Insights | Leadership |
Steve Beuchaw | Vp, Strategic & Bioinsight Finance | Leadership |
Julia Kim | Sr Director, Clinical & Compliance Support | Leadership |
Clara Chong | Commercial Operations - Channel Partner Operations, Asia Pacific, Middle East And Africa | Leadership |
Gavin Worden | Global Director, Audio Visual Services, End User Computing, & Networks | Leadership |
719 more people are available in the full profile.
Complete people profiles for Illumina
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Illumina
Illumina is a publicly listed company on the NASDAQ with ticker symbol ILMN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date24 Nov 2023
- Listed onEuronext: 1ILMN
- Listed entityIllumina, Inc.
- Exchange sectorHealth technology
Financials of Illumina
Figures of Illumina India Biotechnology Private Limited, the primary company behind Illumina, for FY 2025. Revenue was ₹290 Cr (+41% year on year). Net profit was ₹12.67 Cr (4% margin). EBITDA was ₹46.88 Cr (16% margin). Revenue has grown at a compounded annual rate of +366% over three years and +160% over five years.
- ₹290 CrRevenue · FY 2025 · +41% YoY
- ₹12.67 CrNet profit · 4% margin
- ₹46.88 CrEBITDA · 16% margin
- ₹4.99 CrPaid-up capital
- 29Employees (provident fund records)
- +366%Revenue CAGR, 3 years
- +160%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Illumina India Biotechnology Private Limited are on its company page.
Detailed financial statements for Illumina
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Illumina
Illumina has strategically engaged in corporate development activities, having acquired 16 companies. Notable acquisitions include Advanced Liquid Logic, Affomix and Bluebee.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Protein-based assays are developed for life science research. | somalogic.com | Boulder, United States | 1999 | Jun 2025 | $425M | |
Proprietary reagents for single-cell genetic analysis are developed. | fluentbio.com | Watertown, United States | 2018 | Jul 2024 | •••• | |
Circulating tumor DNA is screened for early cancer detection. | grail.com | Menlo Park, United States | 2016 | Sep 2020 | $8B | |
Next-generation sequencing analysis and genomic data compression are provided. | enancio.com | Cesson Sevigne, France | 2015 | Jul 2020 | •••• | |
Cloud-based genomics data analysis solutions are provided for personalized medicine. | bluebee.com | Delft, Netherlands | 2011 | Jun 2020 | •••• | |
Products for genetic sequencing and mutation detection are developed. | conexio-genomics.com | Fremantle, Australia | 2003 | Jan 2016 | •••• | |
Provider of blood platelet-powered molecular diagnostics tests | thrombodx.nl | Amsterdam, Netherlands | 2012 | Jan 2016 | $76.45M | |
Digital LIMS tools are developed for laboratory providers. | genologics.com | Victoria, Canada | 2002 | Aug 2015 | •••• | |
NextBio provides a platform to aggregate and interpret large quantities of genomic data for research and clinical applications. | nextbio.com | Santa Clara, United States | 2004 | Oct 2013 | •••• | |
Bioassay protocols are executed via digital microfluidics technology. | liquid-logic.com | Durham, United States | 2004 | Jul 2013 | $96M |
Complete acquisition details for Illumina
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Illumina
14 dated milestones of Illumina across 32 years, from founding to its latest funding, stage changes and deals.
- Founded Illumina is founded.
- Funding First funding round of $28.0M.
- Acquisition Acquires Advanced Liquid Logic.
- Acquisition Acquires NextBio.
- Acquisition Acquires Genologics.
- Acquisition Acquires ThromboDx.
- Acquisition Acquires Conexio Genomics.
- Funding Latest funding round, Grant,.
- Acquisition Acquires Bluebee.
- Acquisition Acquires Enancio.
- Acquisition Acquires GRAIL.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Fluent BioSciences.
- Acquisition Acquires Somalogic.
Competitors of Illumina
Illumina has 3 listed competitors in our database, 3 of them funded. They include DNAnexus, Seven Bridges Genomics and Hexagon Bio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| dnanexus.com | 2009 | Mountain View, United States | $472.55M | 143 | Cloud-based genome informatics and data management are provided. | |
| sevenbridges.com | 2009 | Cambridge, United States | $113M | 112 | Cloud-based platform to analyze, store, and act on genomic data. | |
| hexagonbio.com | 2017 | Menlo Park, United States | $205.6M | 34 | Bioinformatics tools are provided for analyzing microbial genomic sequencing data. |
Detailed competitors of Illumina
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Illumina
The website of Illumina (illumina.com) receives about 672.7K visits a month and ranks #61,793 among all websites worldwide, #3,849 in Biology.
- Monthly visits672.7K
▼ 7.5% vs previous month
- Unique visitors244.9K
per month
- Global rank#61,793
among all websites
- Category rank#3,849
Science and Education · Biology
- Bounce rate41%
- Pages per visit4.6
- Average visit5 min 49 sec
- DevicesDesktop 60% · Mobile 40%
Websites whose visitors overlap most with Illumina. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| affymetrix.com | 100% | 1.1K | #9,164,392 | View details | |
| completegenomics.com | 100% | 11.4K | #2,001,051 | View details | |
| caliperls.com | 100% | View details | |||
| nimblegen.com | 100% | View details | |||
| sequenom.com | 98% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Illumina
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Illumina (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Illumina
Complete news archive for Illumina
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Illumina
Illumina was founded in 1993 and raised its 1st funding round 7 years after it was founded.
Illumina is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Illumina is a funded company, having raised a total of $28M across 11 funding rounds to date. The company's 1st funding round was a Grant of $1.2M, raised on Jan 2000.
Illumina has 29 employees.
The primary company behind Illumina, Illumina India Biotechnology Private Limited, reported revenue of ₹290 Cr for FY 2025, up 41% year on year.
Developer of technologies for analysis of genetic variation and function. The company provides laboratory instruments, kits, and reagents for research, drug development, and the development of molecular tests. The product categories include gene panel and array finder, microarray kits, clinical research, and IVD products.
Illumina's top competitors include DNAnexus, Seven Bridges Genomics and Hexagon Bio.
Yes, Illumina is publicly traded on NASDAQ under the ticker symbol ILMN.
Illumina has made 16 acquisitions, including Advanced Liquid Logic, Affomix, and Bluebee.
Illumina has 14 investors. Key investors include State Farm, United States Department of Agriculture, HHS, Dow, and Chase.
Illumina operates through Illumina India Biotechnology Private Limited.
The legal entities of Illumina currently have 3 directors, including Amitabh Rath, Ramesh Thamotharan, Frederic Didier Mahieu.